Urinary Clinical Trials

474 recruitingLast updated: July 25, 2026

There are 474 actively recruiting urinary clinical trials across 69 countries. Studies span Not Applicable, Phase 2, Phase 4, Phase 3, Phase 1, Early Phase 1. Top locations include Chicago, Illinois, United States, Houston, Texas, United States, Cleveland, Ohio, United States. Updated daily from ClinicalTrials.gov.


Urinary Trials at a Glance

474 actively recruiting trials for urinary are listed on ClinicalTrialsFinder across 6 cities in 69 countries. The largest study group is Not Applicable with 222 trials, with the heaviest enrollment activity in Chicago, Houston, and Cleveland. Lead sponsors running urinary studies include National Cancer Institute (NCI), Beni-Suef University, and Eli Lilly and Company.

Treatments under study

About Urinary Clinical Trials

Looking for clinical trials for Urinary? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Urinary trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Urinary clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 474 trials

Recruiting
Phase 2

Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer

Prostatic HyperplasiaUrinary Urge IncontinenceStress Urinary Incontinence
National Cancer Institute (NCI)41 enrolled1 locationNCT06161506
Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled582 locationsNCT03866382
Recruiting

Discharge Medication Use Post-Operatively in GU Cancer Patients

Genitourinary Cancer
Wake Forest University Health Sciences684 enrolled1 locationNCT06795087
Recruiting
Early Phase 1

A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

Prostate CancerRadiation ToxicityUrinary Complication
University of Rochester30 enrolled1 locationNCT05530655
Recruiting

Development of an AI-Agent for Urological Disease Diagnosis and Treatment

Prostate CancerBladder CancerUrinary Stones
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University2,000 enrolled3 locationsNCT07721935
Recruiting
Not Applicable

Improving Overactive Bladder Treatment Access and Adherence

Urinary IncontinenceOveractive Bladder Syndrome
Stanford University30 enrolled1 locationNCT06094543
Recruiting
Phase 1

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Triple-Negative Breast CancerEsophageal CancerPancreatic Cancer+11 more
Eli Lilly and Company420 enrolled38 locationsNCT06465069
Recruiting
Phase 3

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Urinary Incontinence, Stress
Eli Lilly and Company1,000 enrolled137 locationsNCT07202884
Recruiting
Not Applicable

Post Approval Effectiveness and Durability Evaluation of the Altaviva™ Tibial Device

Urge Urinary Incontinence
MedtronicNeuro256 enrolled10 locationsNCT07456865
Recruiting

Effect of Group Preoperative Pelvic Floor Training for HoLEP

Urinary IncontinenceBPH
University of California, San Francisco100 enrolled1 locationNCT05719220
Recruiting
Phase 1Phase 2

A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)

Urinary Bladder NeoplasmsBladder Cancer
Merck Sharp & Dohme LLC45 enrolled15 locationsNCT07222488
Recruiting
Phase 1

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

Malignant Solid NeoplasmClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+41 more
M.D. Anderson Cancer Center800 enrolled1 locationNCT03819296
Recruiting

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Heart FailurePainInsomnia+22 more
Duke University5,000 enrolled51 locationsNCT04278404
Recruiting
Phase 1

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

Breast CancerOvarian CancerCervical Cancer+6 more
M.D. Anderson Cancer Center40 enrolled1 locationNCT04038619
Recruiting
Phase 1

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

Malignant Neoplasm of Bone and Articular CartilageMalignant Neoplasms of Female Genital OrgansMalignant Neoplasms of Independent (Primary) Multiple Sites+7 more
M.D. Anderson Cancer Center44 enrolled1 locationNCT03093909
Recruiting
Not Applicable

Consumer Evaluation of an Investigational Intermittent Catheter

Urinary RetentionNeurogenic Bladder
Hollister Incorporated50 enrolled1 locationNCT07714694
Recruiting
Not Applicable

Effectiveness and Acceptability of Insertable Devices for Obstetric Fistula Management

Obstetric fistulaFistulaFistula, Urinary+1 more
University of California, San Francisco100 enrolled3 locationsNCT05444504
Recruiting
Phase 2

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

Breast CancerLiver CancerColorectal, Cancer+19 more
University of California, Irvine75 enrolled1 locationNCT06580002
Recruiting
Not Applicable

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

Prostate CancerProstatectomyBenign Prostatic Hyperplasia+3 more
Axonics, Inc.150 enrolled21 locationsNCT06511141
Recruiting
Phase 3

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Urinary Bladder NeoplasmsNeoplasm MetastasisCarcinoma, Transitional Cell
Eli Lilly and Company450 enrolled286 locationsNCT07218380